Effects of larval exposure to sublethal doses of ivermectin on adult fitness and susceptibility to ivermectin in Anopheles gambiae s.s.
Adult fitness
Anopheles gambiae s.s.
Ivermectin
Mosquito larvae
Journal
Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774
Informations de publication
Date de publication:
21 Aug 2023
21 Aug 2023
Historique:
received:
01
03
2023
accepted:
18
07
2023
medline:
23
8
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
epublish
Résumé
The effects of ivermectin (endectocide) on mosquito survival make it a potential new malaria vector control tool. The drug can be administered to mosquito disease vectors through blood hosts that include humans and livestock. Its increased use may cause contamination of larval habitats, either directly through livestock excreta or indirectly through leaching or run-off from contaminated soil, albeit in sublethal doses. However, the effects of such exposure on immature stages and the subsequent adults that emerge are poorly understood. This study was undertaken to evaluate the impact of ivermectin exposure on Anopheles gambiae s.s. larvae and its effects on fitness and susceptibility to ivermectin in the emerging adults. Laboratory-reared An. gambiae s.s. (Kilifi strain) larvae were exposed to five different ivermectin concentrations; 0, 0.00001, 0.0001, 0.001, and 0.01 ppm, and larval survival was monitored to determine the appropriate sub-lethal dose. Concentrations with survival > 50% (0.00001 and 0.0001 ppm) were selected and used as the sub-lethal doses. The fecundity, fertility, and susceptibility to ivermectin of adults emerging after larval exposure to the sub-lethal doses were examined. Overall, exposure of An. gambiae s.s. aquatic stages to ivermectin caused a dose-dependent reduction in larval survival irrespective of the stage at which the larvae were exposed. Exposure to ivermectin in the larval stage did not have an effect on either the number of eggs laid or the hatch rate. However, exposure of first/second-instar larvae to 0.0001 ppm and third/fourth-instar larvae to 0.001 ppm of ivermectin reduced the time taken to oviposition. Additionally, exposure to ivermectin in the larval stage did not affect susceptibility of the emerging adults to the drug. This study shows that contamination of larval habitats with ivermectin affects An. gambiae s.s. larval survival and could potentially have an impact on public health. However, there are no carry-over effects on the fecundity, fertility, and susceptibility of the emerging adults to ivermectin. In addition, this study shows that environmental exposure to ivermectin in the larval habitats is unlikely to compromise the efficacy of ivermectin in the emerging adults.
Sections du résumé
BACKGROUND
BACKGROUND
The effects of ivermectin (endectocide) on mosquito survival make it a potential new malaria vector control tool. The drug can be administered to mosquito disease vectors through blood hosts that include humans and livestock. Its increased use may cause contamination of larval habitats, either directly through livestock excreta or indirectly through leaching or run-off from contaminated soil, albeit in sublethal doses. However, the effects of such exposure on immature stages and the subsequent adults that emerge are poorly understood. This study was undertaken to evaluate the impact of ivermectin exposure on Anopheles gambiae s.s. larvae and its effects on fitness and susceptibility to ivermectin in the emerging adults.
METHODS
METHODS
Laboratory-reared An. gambiae s.s. (Kilifi strain) larvae were exposed to five different ivermectin concentrations; 0, 0.00001, 0.0001, 0.001, and 0.01 ppm, and larval survival was monitored to determine the appropriate sub-lethal dose. Concentrations with survival > 50% (0.00001 and 0.0001 ppm) were selected and used as the sub-lethal doses. The fecundity, fertility, and susceptibility to ivermectin of adults emerging after larval exposure to the sub-lethal doses were examined.
RESULTS
RESULTS
Overall, exposure of An. gambiae s.s. aquatic stages to ivermectin caused a dose-dependent reduction in larval survival irrespective of the stage at which the larvae were exposed. Exposure to ivermectin in the larval stage did not have an effect on either the number of eggs laid or the hatch rate. However, exposure of first/second-instar larvae to 0.0001 ppm and third/fourth-instar larvae to 0.001 ppm of ivermectin reduced the time taken to oviposition. Additionally, exposure to ivermectin in the larval stage did not affect susceptibility of the emerging adults to the drug.
CONCLUSIONS
CONCLUSIONS
This study shows that contamination of larval habitats with ivermectin affects An. gambiae s.s. larval survival and could potentially have an impact on public health. However, there are no carry-over effects on the fecundity, fertility, and susceptibility of the emerging adults to ivermectin. In addition, this study shows that environmental exposure to ivermectin in the larval habitats is unlikely to compromise the efficacy of ivermectin in the emerging adults.
Identifiants
pubmed: 37605264
doi: 10.1186/s13071-023-05888-w
pii: 10.1186/s13071-023-05888-w
pmc: PMC10441747
doi:
Substances chimiques
Ivermectin
70288-86-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
293Subventions
Organisme : UNITAID
ID : BOHEMIA
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Malar J. 2017 Apr 24;16(1):166
pubmed: 28434405
Am J Trop Med Hyg. 2020 Feb;102(2s):3-24
pubmed: 31971144
PLoS Negl Trop Dis. 2015 May 14;9(5):e0003507
pubmed: 25974081
Trends Parasitol. 2022 Feb;38(2):112-123
pubmed: 34756820
Malar J. 2012 Nov 21;11:381
pubmed: 23171202
Sci Rep. 2017 Aug 17;7(1):8535
pubmed: 28819225
Acta Trop. 2010 Nov;116(2):119-26
pubmed: 20540931
Malar J. 2017 Apr 24;16(1):161
pubmed: 28434401
Malar J. 2011 Apr 10;10:81
pubmed: 21477340
Philos Trans R Soc Lond B Biol Sci. 2021 Feb 15;376(1818):20190810
pubmed: 33357062
Parasit Vectors. 2016 Mar 08;9:131
pubmed: 26951712
Ann Trop Med Parasitol. 2009 Sep;103(6):539-47
pubmed: 19695159
J Infect Dis. 2010 Jul 1;202(1):113-6
pubmed: 20482251
Malar J. 2012 Aug 02;11:261
pubmed: 22856645
PLoS Negl Trop Dis. 2008 Oct 08;2(10):e317
pubmed: 18841205
Lancet Infect Dis. 2022 Apr;22(4):519-528
pubmed: 34919831
Nat Rev Microbiol. 2004 Dec;2(12):984-9
pubmed: 15550944
Integr Environ Assess Manag. 2010 Jul;6 Suppl:567-87
pubmed: 20821718
Parasit Vectors. 2015 Feb 27;8:130
pubmed: 25885477
Malar J. 2017 May 17;16(1):200
pubmed: 28514965
Malar J. 2014 Nov 03;13:417
pubmed: 25363349
Malar J. 2019 Nov 8;18(1):357
pubmed: 31703736
Parasit Vectors. 2021 Mar 20;14(1):172
pubmed: 33743783
Am J Trop Med Hyg. 2002 Dec;67(6):617-22
pubmed: 12518852
Comp Biochem Physiol C Toxicol Pharmacol. 2022 Jan;251:109197
pubmed: 34601086
Aquat Toxicol. 2022 Jul;248:106181
pubmed: 35504174